Overview

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Status:
Terminated

Trial end date:
2017-09-01

Target enrollment:

Participant gender:

Summary

The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).

Phase:

Phase 3

Details

Lead Sponsor:

Ophthotech Corporation

Treatments:

Aflibercept
Bevacizumab